Correction: Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage

Francesco Marampon; Giovanni Luca Gravina; Xiaoming Ju; Antonella Vetuschi; Roberta Sferra; Mathew C. Casimiro; Simona Pompili; Claudio Festuccia; Alessandro Colapietro; Eugenio Gaudio; Ernesto Di Cesare; Vincenzo Tombolini; Richard G. Pestell

doi:10.18632/oncotarget.12267

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage

Francesco Marampon _, Giovanni Luca Gravina, Xiaoming Ju, Antonella Vetuschi, Roberta Sferra, Mathew C. Casimiro, Simona Pompili, Claudio Festuccia, Alessandro Colapietro, Eugenio Gaudio, Ernesto Di Cesare, Vincenzo Tombolini and Richard G. Pestell

PDF | How to cite

Oncotarget. 2016; 7:64526-64526. https://doi.org/10.18632/oncotarget.12267

Metrics: PDF 2441 views | ?

Present: Due to an error made during submission of the revised manuscript, Dr. Giovanni Gravina’s name was spelled incorrectly.

Correct: The correct author list for this manuscript is provided below. Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2016; 7(5):5383-400. DOI: 10.18632/oncotarget.6579

Francesco Marampon^1,^2,^*, Giovanni Luca Gravina^1,^*, Xiaoming Ju², Antonella Vetuschi¹, Roberta Sferra¹, Mathew C. Casimiro², Simona Pompili¹, Claudio Festuccia¹, Alessandro Colapietro¹, Eugenio Gaudio³, Ernesto Di Cesare¹, Vincenzo Tombolini⁴, Richard G. Pestell²

¹ University of L’Aquila, Department of Biotechnological and Applied Clinical Sciences, L’Aquila, Italy
² Department of Cancer Biology, Medical Oncology and Sidney Kimmel Cancer Center, Thomas Jefferson University,Philadelphia, Pennsylvania, USA
³ Department of Human Anatomy, “La Sapienza” University of Rome, Rome, Italy
⁴ Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy
^*These authors contributed equally to this work

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12267

Publication Alerts

Corrections:

Correction: Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage